An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function

Kidney International

Volumn 80, Issue 3, 2011, Pages 282-287

  Holtkamp, Frank A ^a   De Zeeuw, Dick ^a   Thomas, Merlin C ^b   Cooper, Mark E ^b   De Graeff, Pieter A ^a   Hillege, Hans J L ^a   Parving, Hans Henrik ^c   Brenner, Barry M ^d   Shahinfar, Shahnaz ^e   Heerspink, Hiddo J Lambers ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c Mental Health Services CPH   (Denmark)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

angiotensin receptor blocker; chronic kidney disease; diabetic nephropathy; glomerular filtration rate; renal insufficiency; serum creatinine

Indexed keywords

ALBUMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIURETIC AGENT; HEMOGLOBIN; LOSARTAN; PLACEBO;

ADULT; AGED; ALBUMINURIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINARY ALBUMIN CREATININE RATIO; UROGENITAL SYSTEM PARAMETERS;

EID: 79960407033     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.79     Document Type: Article

References (22)

1. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
2. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
3. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
4. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951. (Pubitemid 39447135)
5. Bjorck S, Mulec H, Johnsen SA et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-343.
6. Hillege HL, van Gilst WH, van Veldhuisen DJ et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003; 24: 412-420. (Pubitemid 36286184)
7. Tarnow L, Rossing P, Jensen C et al. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2000; 23: 1725-1730.
8. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-693. (Pubitemid 30140419)
9. Apperloo AJ, de ZD, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51: 793-797. (Pubitemid 27157964)
10. Hansen HP, Rossing P, Tarnow L et al. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 1995; 47: 1726-1731.
11. Levey AS, Adler S, Caggiula AW et al. Effect of dietary protein on the progression of moderate renal disease in the Modification of Diet in Renal Disease study. J Am Soc Nephrol 1996; 7: 2616-2626.
12. Levey AS, Green T, Beck GJ et al. Dietary protein restriction and the progression of chronic renal disease: what have all the results of the MDRD study shown? J Am Soc Nephrol 1999; 10: 2426-2439. (Pubitemid 29501478)
13. Christensen PK, Hansen HP, Parving HH. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int 1997; 52: 1369-1374. (Pubitemid 27496067)
14. Anderson S, Brenner BM. The role of intraglomerular pressure in the initiation and progression of renal disease. J Hypertens Suppl 1986; 4: S236-S238. (Pubitemid 17054511)
15. Anderson S, Brenner BM. Intraglomerular hypertension: implications and drug treatment. Annu Rev Med 1988; 39: 243-253. (Pubitemid 19090799)
16. El-Nahas AM, Paraskevakou H, Zoob S et al. Effect of dietary protein restriction on the development of renal failure after subtotal nephrectomy in rats. Clin Sci (Lond) 1983; 65: 399-406. (Pubitemid 13045105)
17. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-380. (Pubitemid 12188669)
18. Freedberg DE. To eGFR or not to eGFR: here is an intern's answer. Kidney Int 2009; 76: 129-130.
19. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181.
20. Lambers Heerspink HJ, de Zeeuw D. Composite renal endpoints: was ACCOMPLISH accomplished? Lancet 2010; 375: 1140-1142.
21. Brenner BM, Cooper ME, de Zeeuw D et al. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000; 1: 328-335.
22. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)